In this article, we will discuss the 10 Best 52-Week Low Blue Chip Stocks to Buy Now.
With US markets touching all-time highs, foreign markets being relatively cheaper, and global investors being over-indexed to the US markets, ClearBridge Investments believes that it’s easy to envision cascading outflows. Amidst inflation expectations becoming entrenched and concerns related to stagflation, the investment firm sees diversified portfolios of high-quality dividend growers as especially attractive.
Market Breadth Continues to Expand
As per the US Bank, unlike 2023 and 2024, when IT and communication services stocks led most of the S&P 500’s gains, several other sectors remain among this year’s top performers. Notably, industrials, utilities, and financials have been tagged as the top 5 sectors. Therefore, 2025’s YTD results demonstrate broader industry participation. Like recent years, large-cap stocks have been outpacing the mid-cap and small-cap stocks, even though by a lesser margin.
As per Bill Merz (head of capital markets research for U.S. Bank Asset Management Group), the fundamental factors, such as consumer spending and corporate earnings, remain sufficiently strong, enabling investors to look past the tariffs’ impact as of now.
Amidst such trends, we will now have a look at the 10 Best 52-Week Low Blue Chip Stocks to Buy Now.
A business professional banking from their laptop, taking advantage of the company’s investment services.
Our Methodology
To list the 10 Best 52-Week Low Blue Chip Stocks to Buy Now, we used a screener and sifted through several online rankings to shortlist the blue-chip stocks. Next, we chose the ones that are trading close to their respective 52-week lows. We chose the ones popular among hedge funds. We also mentioned the hedge fund sentiments around each stock, as of Q1 2025. Finally, the stocks are arranged in ascending order of their hedge fund sentiments.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Note: All data is as of July 29
10 Best 52-Week Low Blue Chip Stocks to Buy Now
10. Dow Inc. (NYSE:DOW)
Market Price: $25.18
52-week Low: $23.78
Number of Hedge Fund Holders: 43
Dow Inc. (NYSE:DOW) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 25, Goldman Sachs analyst Duffy Fischer maintained a neutral stance on the company’s stock, giving a “Hold” rating. The analyst’s rating is backed by a combination of factors affecting the company’s financial outlook. As per the analyst, Dow Inc. (NYSE:DOW)’s recent financial performance demonstrated a decline in adjusted EBITDA compared to both the previous year and market expectations, highlighting the challenges in meeting earnings targets. In Q2 2025, the company posted operating EBITDA of $703 million compared to $1,501 million in Q2 2024.
Another factor contributing to the analyst’s rating is the uncertainty related to Dow Inc. (NYSE:DOW)’s pricing strategy for polyethylene, which is a critical product. Despite the announcement related to the price increases, the analyst opines that there remains a risk that these might not materialize, potentially weighing on margins. Also, despite a recent dividend cut, there are some concerns about cash flow sustainability, especially if the macroeconomic environment does not improve. That being said, the analyst highlighted that Dow Inc. (NYSE:DOW) noted several one-time cash inflows, which can support its financial position, offering some confidence to the investors.
9. Kimberly-Clark Corporation (NASDAQ:KMB)
Market Price: $127.93
52-week Low: $124.1
Number of Hedge Fund Holders: 45
Kimberly-Clark Corporation (NASDAQ:KMB) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 18, Piper Sandler assumed coverage of the company’s stock with an “Overweight” rating and a price objective of $144, as reported by The Fly. As per the firm’s analyst, the company remains well-placed for long-term growth given its exposure to premium personal care categories. Furthermore, the firm sees Kimberly-Clark Corporation (NASDAQ:KMB)’s valuation as undemanding.
Kimberly-Clark Corporation (NASDAQ:KMB) has also announced that it entered into an agreement with Suzano to form a strategic partnership, establishing a preeminent international tissue and professional products company and sharpening Kimberly-Clark Corporation (NASDAQ:KMB)’s emphasis on the higher growth, higher margin businesses. After the completion of the transaction, Kimberly-Clark Corporation (NASDAQ:KMB) will reduce its exposure to more volatile input costs. This will enhance its ability to deliver more predictable and consistent margins and profit growth.
As per Nelson Urdaneta, Kimberly-Clark Corporation (NASDAQ:KMB)’s Chief Financial Officer, the transaction generates immediate returns and long-term shareholder value as the company captures the upside from a healthier international tissue and professional franchise and accelerates growth and innovation.
8. United Parcel Service, Inc. (NYSE:UPS)
Market Price: $90.84
52-week Low: $87.01
Number of Hedge Fund Holders: 57
United Parcel Service, Inc. (NYSE:UPS) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 29, the company released its Q2 2025 results, wherein its consolidated revenues came in at $21.2 billion. Despite the worries related to the trade policies, in Q2 2025, the overall US economy exhibited continued resilience, but the US small package market was unfavourably impacted by the consumer sentiment, which was near historic lows. In Q2 2025, United Parcel Service, Inc. (NYSE:UPS)’s overall US average daily volume fell by 7.3%. However, because of its strategic actions, the company saw a positive shift in the mix of business, as revenue declined by only 0.8%.
For Q2 2025, United Parcel Service, Inc. (NYSE:UPS) stated that its US domestic generated revenue of $14.1 billion, down marginally compared to last year, mainly because of the decline in Amazon revenue, which was partially mitigated by increases in air cargo and revenue per piece. In Q2 2025, revenue per piece rose 5.5% YoY. Breaking down, the net impact of base rates and package characteristics rose revenue per piece growth rate by 250 bps, customer and product mix improvements by 200 bps, while fuel drove a 100-bps increase.
For FY 2025, United Parcel Service, Inc. (NYSE:UPS) expects capital expenditures of ~$3.5 billion, while dividend payments are expected to be ~$5.5 billion, subject to Board approval. River Road Asset Management, an investment management company, released its Q4 2024 investor letter. Here is what the fund said:
“As of December 31, the portfolio held 29 positions, up four positions from Q3. During Q4, the largest sector increase was 736 bps within industrials, while the largest decrease was -276 bps within consumer discretionary. We established five new positions and eliminated one position
We also initiated a position in United Parcel Service, Inc. (NYSE:UPS) (Cl B) (UPS, 3.0 conviction), the world’s largest package delivery company, which handles over six billion packages annually and can reach 90% of the world’s gross domestic product (GDP) within a day. After years of elevated network investments to expand capacity, UPS has refocused its strategy on growing return on invested capital (ROIC). We believe the stock will rerate higher as margins, which we believe have bottomed, are expected to expand with the price per package growing faster than the cost per package. In the interim, investors collect a 5% dividend, which has grown in 21 out of 24 years since UPS went public. The dividend is supported by healthy free cash flow and an investment grade balance sheet with ~1x net leverage.”
7. Charter Communications, Inc. (NASDAQ:CHTR)
Market Price: $280.68
52-week Low: $274
Number of Hedge Fund Holders: 59
Charter Communications, Inc. (NASDAQ:CHTR) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 28, RBC Capital reduced the price objective on the company’s stock to $370 from $430, while keeping a “Sector Perform” rating, as reported by The Fly. As per the firm’s analyst, Charter Communications, Inc. (NASDAQ:CHTR)’s Q2 2025 EBITDA and broadband subscriber results were below estimates, while its FCF benefited due to the timing of cash taxes and lower capex. Furthermore, the firm added that it now anticipates poorer visibility in the subscriber trends and the probability of lower market share over the long term in competition against fiber and FWA providers.
However, Charter Communications, Inc. (NASDAQ:CHTR) expects that its strategic investments in network evolution and convergence, rural build, US-based service, and seamless entertainment innovation will ramp up future customer and revenue growth. In Q2 2025, the total video customers fell by 80,000 as compared to a fall of 408,000 in Q2 2024. The improvement was because of new and simplified pricing and packaging launched in September 2024. However, early benefits stemming from the inclusion of programmers’ streaming applications in Spectrum’s expanded basic packages also contributed.
Burke Wealth Management, an investment management company, released its Q4 2024 investor letter. Here is what the fund said:
“Charter Communications, Inc. (NASDAQ:CHTR): Charter was a long-time holding for us that we sold in the first quarter of 2024 due to the uncertainty caused by the expiration of the Affordable Connectivity Program (ACP). ACP was a program in which the government paid broadband providers a $30 monthly stipend to connect low income consumers who qualified for the subsidy. This program was put in place during Covid in an effort to keep people connected who were suddenly forced to work or learn from home. I don’t know whether it is more surprising that the program was still in place in early 2024 given that the pandemic has been over for several years or whether the ACP proved to be the one government subsidy that failed to attain permanent status. Either way, the ACP was allowed to expire in May and that meant that the broadband providers had to transition customers who had been receiving the subsidy into paying plans. For Comcast, this equated to ~1.4M customers on a base of 30M which meant that the practical impact of the ACP expiration was little more than the expiration of a major promotion. For Charter, which had over 5M of its roughly 30M subscribers receiving the subsidy, the risks were much greater. Further complicating matters is the fact that Charter targets a debt to EBITDA ratio in the 4.0x-4.5x range as part of its levered equity strategy. This is a great way to boost the returns of a business that targets EBITDA growth in the mid-single-digits but things can get dicey in a hurry should EBITDA begin to contract. Given the uncertainty surrounding the need to wean almost 20% of the subscriber base off of a subsidy that had been in place for several years, we concluded that the risk profile of Charter was no longer one that we could tolerate. When discussing the sale in our Q1-24 Investor Letter, we noted that we would continue to monitor Charter for repurchase should the ACP controversy resolve in an acceptable manner…” (Click here to read the full text)
6. Lockheed Martin Corporation (NYSE:LMT)
Market Price: $420.13
52-week Low: $410.11
Number of Hedge Fund Holders: 68
Lockheed Martin Corporation (NYSE:LMT) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. The company reported Q2 2025 results on July 22. In Q2 2025, the company’s sales of $18 billion saw a sequential growth as it continues to fuel supply chain improvements and ramp capacity on the required deterrent capabilities. Additionally, the company invested $800 million in infrastructure and innovation for growth and returned $1.3 billion to shareholders in the form of dividends and share repurchases.
Lockheed Martin Corporation (NYSE:LMT)’s Aeronautics segment saw an increase of $143 million, or 2% YoY, in sales during the quarter ended June 29, 2025. This was mainly because of increased sales of $470 million on the F-35 program as a result of higher volume on production contracts. This increase was partially mitigated by a $360 million unfavorable cumulative adjustment to sales due to the loss on a classified contract. For FY 2025, Lockheed Martin Corporation (NYSE:LMT) expects sales in the range of ~$73,750 million – $74,750 million, and FCF of between ~$6,600 million – $6,800 million.
Lockheed Martin Corporation (NYSE:LMT)’s Missiles and Fire Control segment witnessed an increase of $331 million, or 11% YoY, in sales during the quarter ended June 29, 2025. This was mainly due to higher sales of $330 million on tactical and strike missile programs because of production ramp-up on Joint Air-to-Surface Standoff Missile (JASSM), Long Range Anti-Ship Missile (LRASM), and precision fires programs.
5. Accenture plc (NYSE:ACN)
Market Price: $278.90
52-week Low: $273.19
Number of Hedge Fund Holders: 69
Accenture plc (NYSE:ACN) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 28, HSBC began coverage of the company’s stock with a “Reduce” rating and a price objective of $240, as reported by The Fly. As per the firm, the market is underestimating the AI disruption risk facing Accenture plc (NYSE:ACN). As per the analyst, early successful generative AI use cases might significantly boost employee productivity in the company’s core offerings, which can translate into pricing pressure over time. Notably, Accenture plc (NYSE:ACN) has agreed to acquire Maryville Consulting Group.
As per Keith Boone, Tech Strategy & Advisory Americas lead at Accenture plc (NYSE:ACN), the acquisition happens to be a strategic step in the company’s ongoing commitment to expanding its technology and digital transformation capabilities to support clients in extracting maximum value from their technology investments. Maryville Consulting Group’s strong expertise in tech strategy and digital operations, along with the healthy partnerships and client relationships, would enhance its ability to help clients use technology as a competitive advantage and drive technology value to achieve business goals.
Aristotle Capital Management, LLC, an investment management company, released its Q1 2025 investor letter. Here is what the fund said:
“Accenture plc (NYSE:ACN), the global IT services and consulting firm, was one of the largest detractors during the period. The company reported revenue at the top end of its guided range, supported by solid booking, particularly in large-scale transformational projects from major corporate clients. Despite these results, shares declined as investor sentiment was impacted by continued client caution amid heightened global uncertainty, including concerns around tariffs and consumer sentiment, as well as the U.S. administration’s initiative to streamline federal operations, which could result in canceled or delayed government contracts. We believe Accenture is well-positioned to support the federal government’s efficiency goals through its expertise and proven track record in delivering innovative, cost-effective solutions. Accenture has also continued to see traction in emerging areas such as generative AI, securing $1.4 billion in new bookings and generating approximately $600 million in related revenue during the quarter. Short-term fluctuations in consulting demand are not unusual, and we remain confident that Accenture’s global scale and deep expertise make it well-positioned to continue to provide solutions and deepen its partnerships with many of the world’s largest companies as they continue to implement increasingly sophisticated technologies.”
4. Bristol-Myers Squibb Company (NYSE:BMY)
Market Price: $46.86
52-week Low: $44
Number of Hedge Fund Holders: 69
Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 31, the company reported results for Q2 2025, wherein it saw healthy momentum throughout its Growth Portfolio and continued to optimize its cost structure. In the back half, Bristol-Myers Squibb Company (NYSE:BMY) remains focused on advancing transformational medicines and delivering on its Growth Portfolio and important pipeline opportunities to shape the growth trajectory. Growth Portfolio revenues came in at $6.6 billion, reflecting 18% growth. This was mainly due to its immuno-oncology (IO) portfolio, Breyanzi, Reblozyl, and Camzyos, and reflects the strength of Cobenfy.
Bristol-Myers Squibb Company (NYSE:BMY) increased its FY 2025 non-GAAP revenue guidance from a ~$45.8 billion – $46.8 billion to ~$46.5 billion – $47.5 billion. This reflects the strength of its Growth Portfolio, better-than-anticipated Legacy Portfolio sales in Q2 2025, and a favorable impact of ~$200 million associated with foreign exchange rates. Bristol-Myers Squibb Company (NYSE:BMY) expects its non-GAAP EPS to be between $6.35 – $6.65.
3. Comcast Corporation (NASDAQ:CMCSA)
Market Price: $32.83
52-week Low: $31.44
Number of Hedge Fund Holders: 81
Comcast Corporation (NASDAQ:CMCSA) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 7, the company announced that it is on the cusp of reaching its goal to double its network energy efficiency, well ahead of the 2030 target. Comcast Corporation (NASDAQ:CMCSA) posted an 11% reduction in energy utilised to power the network and business from 2019 to 2024, using leaner and smarter technologies that process more customer traffic with lower electricity.
Furthermore, Comcast Corporation (NASDAQ:CMCSA)’s network traffic increased 76% from 2019 to 2024, meeting increased customer demand for data fueled by streaming, gaming, sports, and business. Elsewhere, Bloomberg reported that Comcast Corporation (NASDAQ:CMCSA) has increased the price of its Peacock streaming service by $3 a month for new customers starting July 23. This reflects an increase of ~38% for the ad-supported plan. Notably, the version with advertising would increase to $11 a month, while the one without ads would increase to $17. The current customers will witness the rates increase on Aug. 22, highlighted Bloomberg.
2. The Procter & Gamble Company (NYSE:PG)
Market Price: $156.61
52-week Low: $151.9
Number of Hedge Fund Holders: 88
The Procter & Gamble Company (NYSE:PG) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 29, the company reported its FY 2025 results, reporting net sales of $84.3 billion, which remained unchanged compared to the prior year. Notably, a 1% rise because of increased pricing was offset by a 1% decline from unfavorable foreign exchange impacts. However, all-in volume remained unchanged compared to the prior year. Organic sales, excluding the impacts of foreign exchange and acquisitions, and divestitures, rose 2%. The increased pricing and organic volume each resulted in one point of growth in organic sales.
In June 2025, The Procter & Gamble Company (NYSE:PG) announced a portfolio and productivity plan to focus its portfolio and organization to improve the cost structure and competitiveness. The Procter & Gamble Company (NYSE:PG) anticipates incurring non-core restructuring costs of ~$1 billion – $1.6 billion before-tax over 2 years. These activities have a plan to reduce non-manufacturing overhead personnel of up to 7,000 by FY 2027 end. The Procter & Gamble Company (NYSE:PG) expects to incur half of the costs under the plan by FY 2026 end, with the remainder incurring in FY 2027.
For FY 2026, The Procter & Gamble Company (NYSE:PG) projects adjusted FCF productivity of 85% – 90%.
1. UnitedHealth Group Incorporated (NYSE:UNH)
Market Price: $261.07
52-week Low: $248.88
Number of Hedge Fund Holders: 139
UnitedHealth Group Incorporated (NYSE:UNH) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 30, Oppenheimer analyst Michael Wiederhorn reduced the price objective on UnitedHealth Group Incorporated (NYSE:UNH)’s stock to $325 from $400, while keeping an “Outperform” rating, as reported by The Fly. It noted that the company reinstated 2025 adjusted-EPS guidance of $16.00-plus, which can be trough earnings, as UnitedHealth Group Incorporated (NYSE:UNH) returns to growth in 2026 and beyond.
The 2025 guidance assumes performance at the bottom-end or below target ranges throughout Medicare, Medicaid, Commercial, and OptumHealth segments, though the firm opines that such metrics will improve significantly over the upcoming 2 years as UnitedHealth Group Incorporated (NYSE:UNH) re-prices its respective books. The company expects moderate EPS growth in 2026, with acceleration thereafter.
UnitedHealth Group Incorporated (NYSE:UNH) has updated its 2025 outlook, which includes revenues of $445.5 billion – $448.0 billion, net earnings of at least $14.65 per share, and adjusted earnings of at least $16.00 per share. This implies H1 2025 performance and expectations for the balance of the year, including higher realized and anticipated care trends.
Baron Funds, an investment management company, released its Q2 2025 investor letter. Here is what the fund said:
“UnitedHealth Group Incorporated (NYSE:UNH) is a diversified health and well being company with $450 billion in annual revenue, operating across four segments: UnitedHealthcare, Optum Health, Optum lnsight, and Optum Rx. Shares fell sharply during the quarter after the company missed earnings estimates and cut its 2025 earnings per share guidance, citing higher-than-expected medical costs in its Medicare Advantage business. Investor confidence was further shaken in early May by the abrupt departure of CEO Andrew Witty and the suspension of 2025 guidance. The company also mispriced its Medicare Advantage business for 2025—a challenge compounded by reimbursement changes and an influx of newly acquired members who had not been properly risk coded. While we acknowledge UnitedHealth’s potential to restore profitability in this segment over time through disciplined pricing and benefit adjustments, we chose to exit our position during the quarter in favor of other opportunities.
Aside from cash exposure, which accounted for over half of the outperformance in the period, higher exposure to better performing health care distributors and equipment stocks and lower exposure to Benchmark heavyweight UnitedHealth Group Incorporated in managed health care accounted for most of the remaining relative gains. UnitedHealth’s shares fell sharply during the quarter after the company missed earnings estimates and cut its 2025 EPS guidance, citing higher-than-expected medical costs in its Medicare Advantage business. Investor confidence was further shaken in early May by the abrupt departure of CEO Andrew Witty and the suspension of 2025 guidance. UnitedHealth has historically commanded a premium valuation, reflecting its scale advantages, integrated care model, industry-leading innovation, and consistent execution.
We sold UnitedHealth Group Incorporated because the company lowered guidance shortly after reporting earnings and then suspended guidance shortly after that. Management cited three issues: greater-than-expected impact from the health status of new members, higher-than-expected cost trends in the Medicare Advantage business, and a broadening of this higher trend to the Medicaid and commercial business. Some of these issues could potentially be fixed in the short term through repricing, but we felt management’s lack of visibility raised too many questions about the long-term earnings potential of the business. We plan to revisit the investment thesis after new management conducts its comprehensive review and resets earnings guidance.”
While we acknowledge the potential of UNH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than UNH and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
